Structure Therapeutics Reports Strong Q4 Net Income, $1.4B Cash Runway, and Positive Phase 2 Obesity Drug Data
GPCR has more than doubled off its 52-week low of $13.22.
Summary
Structure Therapeutics reported a Q4 2025 net income of $33.0 million, a $1.4 billion cash runway through 2028, and positive Phase 2 data for its oral GLP-1 agonist aleniglipron, showing up to 15.3% weight loss.
Key Events · Product Development and Regulatory · GPCR
-
Strong Q4 Financial Performance
The company reported a net income of $33.0 million for the fourth quarter of 2025, a significant improvement from a $36.5 million net loss in the prior year, primarily due to $100.0 million in other license income and $10.2 million in gains from asset sales.
-
Extended Cash Runway Through 2028
Structure Therapeutics ended 2025 with $1.4 billion in cash, cash equivalents, and short-term investments, which is expected to fund operations and key clinical milestones through the end of 2028.
-
Positive Phase 2 Aleniglipron Data
The oral GLP-1 receptor agonist, aleniglipron, demonstrated significant weight loss in Phase 2 ACCESS programs, with up to 15.3% placebo-adjusted mean weight loss at 36 weeks with the 240 mg dose, showing no plateau.
-
Phase 3 Initiation for Aleniglipron Planned
Following positive Phase 2 results and an upcoming End-of-Phase 2 meeting with the FDA, the company anticipates initiating its Phase 3 registrational program for aleniglipron in the second half of 2026.
Analysis · GPCR · Life Sciences
Structure Therapeutics reported a significant turnaround to net income in Q4 2025, driven by substantial license income and asset sales, which also contributed to a robust cash position of $1.4 billion, extending their runway through 2028. This financial stability provides a strong foundation for advancing their pipeline. Critically, the company provided positive updates on its lead obesity candidate, aleniglipron, highlighting up to 15.3% weight loss in Phase 2 studies and confirming plans for Phase 3 initiation in the second half of 2026. The expansion of their oral small molecule amylin receptor agonist pipeline with two candidates entering or initiating Phase 1 further diversifies their growth potential in the competitive metabolic disease market. Investors should monitor the upcoming 44-week data from the ACCESS II study and the progress towards Phase 3.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 42.5% of the 522 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GPCR was trading at $64.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $13.22 to $94.90. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.